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BioequivalenceAbstract Background: The selection of a robust bioequivalence (BE) study designs for registering
a generic product remains still a hard task. This task is still challenging despite the fact that generic
products are much needed by health care providers in economical terms. Thus, BE study designs
could be a means to allow companies to reduce costs and reach the market earlier. We therefore
investigated whether different approaches in various products assessed by the European Medicines
Agency during the approval phase resulted in a reduction in resources required to show bioequiv-
alence for different medicinal products.
Methods: European Public Assessment Reports (EPARs) for off-patent medicinal products
authorised within the European Union (EU) through the centralised procedure during the period
2007–2015 were retrieved and reviewed to identify the clinical studies that resulted in fewer number
of subjects, the number of centres or trial duration versus the two-period crossover design.
Results: 7 studies out of 108 were considered as having beneﬁtted from having a different design.
Differences noted included having a different dose allocation scheme, having a different number of
dosing periods, having a different number of treatment arms, and having one study evaluating dif-
ferent strengths. Beneﬁts noted included a decrease in the number of subjects and centres required,(BCS);
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perspective. Saudi Pharmaceutical Journal (2decreases in study duration and a reduced number of studies required to demonstrate bioequiva-
lence.
Conclusion: Bioequivalence studies can be designed in a speciﬁc manner to require fewer
resources to carry out. Fewer resources required to register a medicinal product, could impart an
advantage to companies (such as to be ﬁrst on the market) or could even translate to making
medicines more accessible (such as cheaper) to patients.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In the European Union (EU) a medicinal product needs a mar-
keting authorisation (MA), to be placed on the market. The
EU’s medicinal products’ legislative framework allows for a
reduced application for medicines outside their data exclusiv-
ity. Such applications include generic medicinal products.
Generic products are deﬁned within the EU by article 10.1
of Directive 2001/83/EC (Directive 2001/83/EC, 2012) as
‘‘medicinal product[s] [having] the same qualitative and quan-
titative composition in active substances and the same pharma-
ceutical form as the reference medicinal product, and whose
bioequivalence with the reference medicinal product has been
demonstrated by appropriate bioavailability studies.” In the
EU, the Committee for Medicinal Products for Human Use
(CHMP) guideline on bioequivalence (BE) requires that bioe-
quivalence studies are carried out to show that the rate and
extent of absorption of test product are equivalent to reference
product. In the EU, the CHMP Guideline on the investigation
of bioequivalence was ﬁrst published in 1998 and subsequently
updated (the last update was in 2010) (CHMP, 2010a). In the
US, the FDA deﬁne BE as the absence of a signiﬁcant differ-
ence in the rate and extent the active ingredient becoming
available at the drug action site when administered at the same
molar dose under similar conditions in an appropriately
designed study. Products classiﬁed as generics require less
research and development compared to originator products.
The MA of a generic medicinal product is supported by bioe-
quivalence (BE) studies instead of full clinical trials for safety
and efﬁcacy. A biowaiver may also be requested instead of the
BE studies, when justiﬁed, in line with the Biopharmaceutics
Classiﬁcation System (BCS) as per CHMP guideline
(CHMP, 2010a). As a result the resources required in bringing
these products to market are hence substantially lower than
those for the originator products.
The aim of a generic manufacturer’s pharmaceutical devel-
opment was to develop me-too medicines (i.e. copies), because
if a bio-‘‘better”medicinal product (for example, a formulation
with a better bioavailability then the reference product) is devel-
oped, the applicant would not be able to register the product as a
generic medicinal product. However, the drive to be the ﬁrst
company to reach the market with its generic product so that
it beneﬁts from aperceived ‘ﬁrstmover’ advantage and thus sub-
sequently a potential signiﬁcant market share over subsequent
generics, is driving generic companies to explore how to reduce
further the resources required in bringing generics to market
(Grabowski et al., 2011). This effort generally results in generic
drugs having lower prices compared to the originator (King and
Kanavos, 2002). By encouraging the use of such products,
NationalHealth Systems (NHSs) beneﬁt from substantial ﬁnan-. et al., Changing paradigms in bioequi
016), http://dx.doi.org/10.1016/j.jsps.20cial savings (Duerden and Hughes, 2010). The market for gen-
eric drugs is very competitive, as several companies may
market the same active pharmaceutical ingredient (API) follow-
ing expiry of the originator product’s market exclusivity period
(Reiffen andWard, 2005). In the EU, the standard study design
expected for a generic medicine is the randomised, two-period,
two-sequence, single-dose crossover design (a crossover design
is a repeated measurements design where each patient receives
different treatments during the different time periods; the paral-
lel design is one where patients are randomised to a treatment
and remain on that treatment throughout the duration of the
trial) as per CHMP guideline on the investigation of bioequiva-
lence (please note that the Guideline should be read in conjunc-
tion with several guidelines (such as Pharmacokinetic studies in
man)) (CHMP, 2010a).However, based upon our experience (as
regulators) in evaluating generic medicinal products for human
use, we noticed in our assessments different approaches used for
BE study designs. This intrigued us to explore further whether
the design of such studies was becoming more common and
whether they ultimately led to fewer resources required to bring
the generic to themarket. For this aim, we looked at all the stud-
ies submitted to support theMAs of generics issued by the Euro-
pean Commission through the centralised procedure, from
September 2007 till February 2015.2. Materials and methods
All the generic products authorised through the centralised
procedure (from September 2007 till February 2015) in the
EU were extracted from the European Medicines Agency
(EMA) database of centrally approved medicinal products
for human use, see: http://www.ema.europa.eu/ema/index.
jsp?curl=pages/medicines/landing/epar_search.jsp&mid=
WC0b01ac058001d124 (European Medicines Agency, 2015a).
The European Public Assessment Report (EPAR) was
retrieved for each different product and the relevant BE studies
were reviewed to identify the following:
(1) Any studies that were not the randomised, two-period,
two-sequence, single-dose crossover design.
(2) Differences in design from other studies submitted for
the same API.
(3) Differences in the resources (speciﬁcally, identifying
reductions in the number of subjects required, the time
frame of the study and the number of centres involved
for the study) between studies submitted for the sameAPI.
Descriptive statistics for the different products and studies
were carried out.valence trials submitted to the EMA for evaluation – A clinical and regulatory
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Table 2 Study designs submitted.
Study design Studies
Crossover 103
Parallel 5
Table 3 Number of dosing periods designed.
Number of dosing periods Studies
One 5
Two 91
Three 4
Four 9
Table 4 Number of arms designed.
Number of arms Studies
Two 102
Three 6
Changing paradigms in bioequivalence trials 33. Results
3.1. Review of the EPARs for generic medicinal products
authorised in the EU (Sep 2007-Feb 2015)
A total of 148 generic products were reviewed (includes both
products authorised and 1 product refused) in the EU from
September 2007 till February 2015 for 38 different active
substances. BE studies were conducted for 32 out of these
38 substances (84.2%). The other 6 APIs containing atosi-
ban, busulfan, docetaxel, methylthioninium, topotecan and
zoledronic acid, were exempted from such studies, all due
to being formulations intended for parenteral use, which is
in line with CHMP guideline on the investigation of
bioequivalence (2). Out of the 32 substances for which BE
studies were carried out, there were 22 active substances
(68.8%) for which more than one generic product was autho-
rised. Medicinal Products containing these 22 substances
were submitted with a total of 108 BE studies. The results
are shown in Table 1.
Out of these 108 BE studies, 103 employed a crossover
design (95.4%) while 5 employed a parallel design. The major-
ity of studies, 91, had two dosing periods (84.3%), 5 had one
dosing period, all due to being parallel studies (4.6%), 4 had
three dosing periods (3.7%) and 8 had four dosing periods
(7.4%). A two-arm comparative design was used for 102 stud-
ies (94.4%) and 6 studies (5.6%) opted for a three-arm design.
A total of 107 studies (99.1%) were single-dose studies, while 1
study, C11-1612 (RIVASTIGMINE 3M HEALTHCARE
LTD (Procedure EMEA/H/C/003824)) (CHMP, 2014) had
both single- and multiple-dose components which is under-
standable since the BE study was used to support a transder-
mal patch. The results are shown in Tables 2–4.
Analysing the BE studies submitted for the same active sub-
stance by different marketing authorisation holders, 7 out of
108 BE studies (6.5%) were identiﬁed to be different in design
from other studies submitted for the same API. Therefore, it
was interesting to understand whether these differences could
impact the resources required to carry out the studies com-
pared to the two-period, two-sequence, single-dose crossover
design.
3.2. Description of the studies identified
The 108 studies were then analysed and the following themes
identiﬁed:Table 1 Descriptive statistics for products and studies
reviewed.
Generic products 148
Active Pharmaceutical Ingredients (APIs) 38
APIs having BE studies 32
APIs revieweda 22
BE studies carried out for reviewed APIs 108
Diﬀerent innovative studies identiﬁed 7
Diﬀerent themes noted 4
a Reviewed APIs had BE studies available and were available as
more than one product.
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3.2.1. Differences in dose allocation
Out of the 108 studies, 1 had a dosing scheme based upon the
participants’ body surface area (BSA) as compared to other
trials on the same active substance. Where studies designed
on BSA versus ﬁxed dosing resulted in differences in the num-
ber of study centres and patients recruited as follows.
3.2.1.1. Capecitabine: EMA Procedure: EMEA/H/C/002050/
0000. 5 generic products were authorised from September 2007
till February 2015: CAPECITABINE SUN (EMA procedure
no: EMEA/H/C/002050/0000) (CHMP, 2013a); CAPECITA-
BINE ACCORD (EMEA/H/C/002386) (CHMP, 2012a);
CAPECITABINE MEDAC (EMEA/H/C/002568) (CHMP,
2012b); CAPECITABINE ECANSYA (EMEA/H/C/002605)
(CHMP, 2012c); CAPECITABINE TEVA (EMEA/H/
C/002362) (CHMP, 2012d). The studies used to support the
MAs of these 5 generic products are listed in Table 5.
1 bioequivalence study (CPB 500T IR 3265 11(a)) was sub-
mitted to support CAPECITABINE SUN (CHMP, 2013a).
CPB 500T IR 3265 11(a) employed a different dosing scheme
compared to other studies submitted in support of the market-
ing authorisation for other capecitabine containing products.
Study 438-08 submitted in support of CAPECITABINE
ACCORD (CHMP, 2012a), CAPECITABINE MEDAC
(CHMP, 2012b) and CAPECITABINE ECANSYA (CHMP,
2012c) and studies 130/09-06.CE and 005/10-06.CE submitted
for CAPECITABINE TEVA (CHMP, 2012d) all followed a
ﬁxed dosing scheme.
Study CPB 500T IR 3265 11(a) was a randomised, open-
label, two-treatment, four-period, two-sequence, replicate
crossover, single dose BE study aiming to establish thealence trials submitted to the EMA for evaluation – A clinical and regulatory
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Table 5 Generic Capecitabine medicinal products authorised in the EU.
Procedure number Product name Study Finalised regulatory
evaluation (Year)
EMEA/H/C/002050/0000 CAPECITABINE SUN CPB 500T IR 3265 11(a) 2013
EMEA/H/C/002386 CAPECITABINE ACCORD 438-08 2012
EMEA/H/C/002568 CAPECITABINE MEDAC 438-08 2012
EMEA/H/C/002605 ECANSYA (PREVIOUSLY
CAPECITABINE KRKA)
438-08 2012
EMEA/H/C/002362 CAPECITABINE TEVA 130/09-06.CE and 005/10-06.CE 2012
4 N. Refalo et al.comparative BE of CAPECITABINE SUN 500 mg ﬁlm-
coated tablets. The reference product used was XELODA
500 mg ﬁlm-coated tablets. The formulations were adminis-
tered to cancer patients under fed conditions.
Study CPB 500T IR 3265 11(a) was conducted in ﬁve differ-
ent centres. The subjects were grouped and dosed based upon
their BSA. Subjects having a BSA less than 1.26 m2 received a
total daily dose of 3000 mg of capecitabine, subjects with BSA
between 1.53 and 1.66 m2 received a daily dose of 4000 mg and
subjects with a BSA between 1.93 and 2.06 m2 received a daily
dose of 5000 mg. The test and reference formulations were
administered thirty minutes after administration of a high fat
high calorie breakfast, on each of days 1–4, representing peri-
ods I–IV. All of the subjects received 2 mg intravenous grani-
setron thirty minutes (±10 min) prior to each dose.
Study CPB 500T IR 3265 11(a) enroled ﬁfty (50) subjects
while the other three studies, study 438-08, study 130/09-06.
CE and study 005/10-06.CE, had a mean of seventy-seven sub-
jects (n= 3, range 70–88). In addition study CPB 500T IR
3265 11(a) was conducted in ﬁve (5) different sites as opposed
to the ﬁxed dose, two-period study 438-08, used to support
granting of the MA for CAPECITABINE ACCORD, CAPE-
CITABINE MEDAC and ECANSYA, which study was con-
ducted in thirteen (13) different centres. The duration of the
clinical part of study CPB 500T IR 3265 11(a) was not speci-
ﬁed in the CAPECITABINE SUN EPAR.
3.2.2. Differences in the number of dosing periods
Out of the 108 studies reviewed 8 studies had four dosing peri-
ods (Refer to Table 6):
 3 studies related to Capecitabine (studies 130/09-06.CE
(CHMP, 2012d); 005/10-06.CE (CHMP, 2012d) and CPB
500T IR 3265 11(a) (CHMP, 2013a)).
 1 study related to Clopidogrel (2009–2089) (CHMP, 2011a).Table 6 Generic medicinal products submitted with studies having
Procedure number Product name
EMEA/H/C/002362 CAPECITABINE TEVA
EMEA/H/C/002050/0000 CAPECITABINE SUN
EMEA/H/C/001226 CLOPIDOGREL TEVA PHARMA B.V
EMEA/H/C/002025 IASIBON
EMEA/H/C/001195 IBANDRONIC ACID TEVA
EMEA/H/C/1218 MYCLAUSEN
EMEA/H/C/002676/0000 ACTELSAR HCT
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2010b, 2011b) and IAT-P7-289 (CHMP, 2010c)).
 1 study related to Mycophenolate (Study 3668) (CHMP,
2010d).
 1 study related Telmisartan/Hydrochlorothiazide (study
2335/11) (CHMP, 2013b).
3.2.2.1. Capecitabine – EMA Procedures EMEA/H/C/002362,
EMEA/H/C/002050/0000. Studies, 130/09-06.CE and 005/10-
06.CE (Procedure EMEA/H/C/002362) (CHMP, 2012d) and
CPB 500T IR 3265 11(a) (Procedure EMEA/H/
C/002050/0000) (CHMP, 2013a) followed a four-period
design. While Study 438-08 submitted in support for granting
of an MA for CAPECITABINE ACCORD (Procedure
EMEA/H/C/002386) (CHMP, 2012a), CAPECITABINE
MEDAC (Procedure EMEA/H/C/002568) (CHMP, 2012b)
and ECANSYA (Procedure EMEA/H/C/002605) (CHMP,
2012c) followed a two-period design.
Study CPB 500T IR 3265 11(a) has already been described in
the previous section. Study 130/09-06.CE and Study 005/10-06.
CE, were both randomised, open-label, two-treatment, four-
period, two-sequence, replicate crossover, single dose BE stud-
ies. The two studies aimed to evaluate the BE of CAPECITA-
BINE TEVA 150 mg tablets and 500 mg tablets respectively,
with the reference XELODA equivalent strength tablets.
Subjects in Study 130/09-06.CE, all undergoing a treatment
cycle of capecitabine chemotherapy, were administered a ﬁxed
dose of 1950 mg made up of 150 mg tablets on the mornings of
days 1, 2, 8 and 9, representing periods I–IV. The doses were
administered following a high-fat high-calorie breakfast. The
evening dose was of the product normally used during the rest
of the treatment cycle. The same procedure was followed for
Study 005/10-06.CE, with the exception that subjects received
a ﬁxed dose of 2000 mg made up of 500 mg tablets.four dosing periods.
Study Finalised regulatory
evaluation (Year)
130/09-06.CE and 005/10-06.CE 2012
CPB 500T IR 3265 11(a) 2013
. 2009-2089 2011
IAT-P9-457 2010
IAT-P7-289 2010
Study 3668 2010
2335/11 2013
valence trials submitted to the EMA for evaluation – A clinical and regulatory
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Changing paradigms in bioequivalence trials 5All four-period studies conducted for capecitabine-
containing products (i.e. studies 130/09-06.CE; 005/10-06.CE
and CPB 500T IR 3265 11(a)) had an average of (64) sixty-
four subjects (n= 3, range 50–72). In contrast, the two-
period Study 438-08 (Procedures EMEA/H/C/002386,
EMEA/H/C/002568 and EMEA/H/C/002605) submitted to
support the granting of an MA for CAPECITABINE
ACCORD (CHMP, 2012a), CAPECITABINE MEDAC
(CHMP, 2012b) and ECANSYA (CHMP, 2012c) had (88)
eighty-eight subjects (see Table 5).
In terms of study duration, the four-period capecitabine
studies were of the following lengths: 5 months (13 April to
13 September 2010) for Study 130/09-06.CE and 3 months
(19 July to 26 October 2010) for Study 005/10-06.CE. In con-
trast the clinical portion of the two-period study (Study 438-
08) lasted around six months (1 September 2009 to 25 Febru-
ary 2010).
3.2.2.2. Clopidogrel–EMA Procedure EMEA/H/C/001226. For
generic products containing clopidogrel (n= 24), 1 study was
submitted which followed a four-period design while 9 studies
were submitted following a two-period design. In total 10 stud-
ies were used to support the MAs of 24 clopidogrel medicinal
products (this is possible as parallel procedures are acceptable
upon regulatory ﬁling; see Table 6). The four-period study
2009–2089 conducted for CLOPIDOGREL TEVA PHARMA
B.V (Procedure EMEA/H/C/001226) (CHMP, 2011a) enroled
96 subjects. From a total of 9 two-period studies, 8 speciﬁed
the number of subjects which had a mean of 70 subjects (range
23–117). Thus it seems that a four-period design did not have a
reduction in the number of subjects required for the study.
3.2.2.3. Ibandronic acid – EMA procedures EMEA/H/C/2025,
EMEA/H/C/002367, EMEA/H/C/001195. There were only 2
studies submitted for products containing ibandronic acid,
which both followed a four-period design: Study IAT-P9-457
submitted for both IASIBON (Procedure EMEA/H/C/2025;
Finalised Regulatory Evaluation Year 2010) (CHMP, 2010b)
and IBANDRONIC ACID SANDOZ (Procedure EMEA/H/
C/002367; Finalised Regulatory Evaluation Year 2011)
(CHMP, 2011b) and study IAT-P7-289 submitted for IBAN-
DRONIC ACID TEVA (Procedure EMEA/H/C/001195;
Finalised Regulatory Evaluation Year 2010) (CHMP, 2010c).
Therefore, since no studies have been submitted with a two
period design to support a marketing authorisation with iban-
dronic acid it was not possible to compare these studies with
the four-period studies for ibandronic acid.
3.2.2.4. Mycophenolate – EMA procedure EMEA/H/C/001218.
Study 3668, submitted as support for the granting of an MA
for MYCLAUSEN (Procedure: EMEA/H/C/001218)
(CHMP, 2010d) was conducted to verify the BE of the test
product, after a previous two-period study on the same pro-
duct, and Study 411-87-06-02-0001 (Procedure: EMEA/H/
C/001218) (CHMP, 2010d), had been inconclusive. As a result,
study 3668 could not be considered as having been designed in
order to prove the product’s BE on its own. Comparison with
other studies is therefore not suitable.
3.2.2.5. Telmisartan/Hydrochlorothiazide – EMEA/H/C/
002676/0000. Out of two studies submitted for telmisartan/h
ydrochlorothiazide combination products one, Study 2335/11Please cite this article in press as: Refalo, N. et al., Changing paradigms in bioequiv
perspective. Saudi Pharmaceutical Journal (2016), http://dx.doi.org/10.1016/j.jsps.20(Procedure EMEA/H/C/002676/0000) (CHMP, 2013b) sub-
mitted to support the granting of an MA for ACTELSAR
HCT, was a four-period study (see Table 7). The other study,
Study 10-302, submitted as support for granting of an MA for
TOLUCOMBI (Procedure EMEA/H/C/002549) (CHMP,
2013c), was a two-period study.
Study 2335/11, was a randomised, open-label, two-
treatment, four-period, two-sequence, replicate crossover, sin-
gle dose BE study evaluating the BE of ACTELSAR HCT
80 mg/25 mg tablets with MICARDIS PLUS 80 mg/25 mg
tablets under fasting conditions.
The number of subjects enroled differed between the stud-
ies, where Study 2335/11 had 48 subjects, while Study 10-302
enroled 70 subjects. Duration of the studies was not speciﬁed
in the EPARs.
3.2.3. Different number of arms
Out of the 108 studies reviewed, 6 had three arms, as opposed
to two arms (see Table 8).
 1 study related to Desloratadine (Study 90044) (CHMP,
2012e).
 1 study related to Imatinib (Study IAI-P1-453) (CHMP,
2013d).
 1 study related to Temozolomide (Study PKD-08-054)
(CHMP, 2011c).
 1 study related to Irbesartan (Study 1056) (CHMP, 2009a).
 2 studies related to Olanzapine (Study 60679 and study
A37552) (CHMP, 2012f, 2009b–e).3.2.3.1. Desloratadine – EMA Procedure EMEA/H/C/002404.
Study 90044 submitted as support for the granting of an MA
for DESLORATADINE RATIOPHARM (Procedure
EMEA/H/C/002404) (CHMP, 2012e) was designed to com-
pare the test product with both the EU and the Canadian ref-
erence products. However, only results for comparison with
the EU product are presented in the EPAR for the product,
and therefore, comparison with other three-armed studies is
not possible. One possible reason why the results for compar-
ison with the Canadian reference product were not reported in
the EPAR could be due to the reference product being sourced
from outside the EU and the relevant results were used to reg-
ister the generic product in a different regulatory region.
3.2.3.2. Imatinib – EMA Procedure EMEA/H/C/002594. Study
IAI-P1-453, submitted as support for the granting of an MA
for IMATINIB ACTAVIS (Procedure EMEA/H/C/002594)
(CHMP, 2013d) was designed to compare the test product with
both the EU and the United States (US) reference products. As
with DESLORATADINE RATIOPHARM, only results for
comparison with the EU product are presented in the EPAR
for the product, and therefore, comparison with other three-
armed studies is not possible. The same reason as before could
explain why this occurred, that possibly, the results for com-
parison of the generic product with the US reference product,
were used to register the generic product in a different regula-
tory region.
3.2.3.3. Temozolomide – EMA procedure EMEA/H/C/002198.
Study PKD-08-054, submitted as support for the granting of
an MA for TEMOZOLOMIDE SUN (Procedure EMEA/H/alence trials submitted to the EMA for evaluation – A clinical and regulatory
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Table 7 Generic Telmisartan/Hydrochlorothiazide medicinal products authorised in the EU.
Procedure number Product name Study Finalised regulatory evaluation (Year)
EMEA/H/C/002549 TOLUCOMBI 10-302 2013
EMEA/H/C/002676/0000 ACTELSAR HCT 2335/11 2013
Table 8 Generic medicinal products submitted with studies having three arms.
Procedure number Product name Study Finalised regulatory evaluation (Year)
EMEA/H/C/002404 DESLORATADINE RATIOPHARM 90044 2012
EMEA/H/C/002594 IMATINIB ACTAVIS IAI-P1-453 2013
EMEA/H/C/001093 IRBESARTAN TEVA 1056 2011
EMEA/H/C/000810 OLANZAPINE TEVA A37552 2009
EMEA/H/C/001085 OLANZAPINE GLENMARK 60679 2009
EMEA/H/C/001086 OLANZAPINE GLENMARK EUROPE 60679 2009
EMEA/H/C/001087 OLAZAX 60679 2009
EMEA/H/C/001088 OLAZAX DISPERZI 60679 2009
EMEA/H/C/002198 TEMOZOLOMIDE SUN PKD-08-054 2009
6 N. Refalo et al.C/002198) (CHMP, 2011c), was designed to compare the test
product with both the EU and the US reference product. How-
ever, as with DESLORATADINE RATIOPHARM and
IMATINIB ACTAVIS only the results for comparison with
the EU product are presented in the EPAR for TEMOZOLO-
MIDE SUN, and therefore, comparison with other three-
armed studies is not possible. As before, it is possible that
the results for comparison with the US reference product were
used to support the registration of the generic product in a dif-
ferent regulatory region.
3.2.3.4. Irbesartan – EMA procedure EMEA/H/C/001093. A
total of 3 studies were submitted for 3 generic products con-
taining irbesartan. Study 1056 submitted as support for the
granting of an MA for IRBESARTAN TEVA (Procedure
EMEA/H/C/001093) (CHMP, 2009a) was designed to com-
pare two batches of the test product with the reference pro-
duct; thus, it had 3 arms. Study GE03IRB/1/06 submitted in
support for granting of an MA for SABERVEL (Procedure
EMEA/H/C/002510) (CHMP, 2012g) and Study IBA-P7-064
submitted in support for granting of an MA for IFIRMASTA
(Procedure EMEA/H/C/000962) (CHMP, 2008a) followed a
two-arm design.
The three-armed study, 1056, enroled 24 subjects, while the
two-arm studies GE03IRB/1/06 enroled 29 subjects and IBA-
P7-064 enroled 24 subjects. Therefore the number of arms does
not seem to inﬂuence the number of subjects required for
irbesartan-containing products (see Table 9).
3.2.3.5. Olanzapine – EMEA/H/C/001085, EMEA/H/C/
001088, EMEA/H/C/001086, EMEA/H/C/001087, EMEA/H/
C/000810. Out of the 11 studies submitted for 9 olanzapine-
containing products (see Table 10), the following two studies
had a three-arm design: Study A37552, submitted for the
granting of an MA for OLANZAPINE TEVA (Procedure
EMEA/H/C/000810) (CHMP, 2012f) and Study 60679, for
OLANZAPINE GLENMARK (Procedure EMEA/H/
C/001085) (CHMP, 2009b), OLANZAPINE GLENMARK
EUROPE (Procedure EMEA/H/C/001086) (CHMP, 2010g),
OLAZAX (Procedure EMEA/H/C/001087) (CHMP, 2009d)Please cite this article in press as: Refalo, N. et al., Changing paradigms in bioequi
perspective. Saudi Pharmaceutical Journal (2016), http://dx.doi.org/10.1016/j.jsps.20and OLAZAX DISPERZI (Procedure EMEA/H/C/001088)
(CHMP, 2009e).
The other nine studies submitted for olanzapine-containing
products were all two-arm studies: Studies BS590 and BS591
for OLANZAPINE MYLAN (Procedure EMEA/H/
C/000961) (CHMP, 2008b), Study 007/05 for OLANZAPINE
CIPLA (Procedure EMEA/H/C/000793) (CHMP, 2007a),
Studies 2006-1152 and B0507, both submitted for OLANZA-
PINE TEVA as well (Procedure EMEA/H/C/000810)
(CHMP, 2012f), Protocols 012645 and AA25817, both submit-
ted for ZALASTA (Procedure EMEA/H/C/000792) (CHMP,
2007b) and Studies OL 5063 and OAN-P8-57.1, both for
OLANZAPINE APOTEX (Procedure EMEA/H/C/001178)
(CHMP, 2010e).
Study A37552 (CHMP, 2012f) was three-treatment, three-
period, three-sequence, crossover, single dose BE study evalu-
ating the BE of OLANZAPINE TEVA 20 mg orodispersible
tablets. Two reference products were used: ZYPREXA VELO-
TAB 20 mg orodispersible tablets and ZYPREXA 20 mg ﬁlm-
coated tablets. After an overnight fast, which continued for
four hours post-dosing, the subjects received one of the olan-
zapine formulations. The ﬁlm-coated tablet, when given, was
administered with water, while the orodispersible tablets were
administered without water.
Study 60679, submitted to evaluate the BE of OLANZA-
PINE GLENMARK (Procedure EMEA/H/C/001085)
(CHMP, 2009b), OLANZAPINE GLENMARK EUROPE
(Procedure EMEA/H/C/001086) (CHMP, 2009c), OLAZAX
(Procedure EMEA/H/C/001087) (CHMP, 2009d) and OLA-
ZAX DISPERZI (Procedure EMEA/H/C/001088) (CHMP,
2009e). similar to Study A37552, was also a three-arm study
with two reference products, one being a ﬁlm-coated tablet
and the other an orodispersible tablet. This time, the strength
used was of 10 mg. However, study 60679, consisting of two
dosing periods, differed from study A37552 which had been
a three-period study. Study 60679 was hence a two-period
crossover study, where participants received the test formula-
tion in one dosing period and the other dosing period involved
the administration of either the reference ﬁlm-coated tablet or
the reference orodispersible tablet.valence trials submitted to the EMA for evaluation – A clinical and regulatory
16.07.005
Table 10 Generic Olanzapine medicinal products authorised in the EU.
Procedure number Product name Study Finalised regulatory
evaluation (Year)
EMEA/H/C/000792 ZALASTA Protocol 012645, Protocol AA25817 2007
EMEA/H/C/000793a OLANZAPINE CIPLA 007/05 2007
EMEA/H/C/000810 OLANZAPINE TEVA 2006-1152, B0507, A37552 2009
EMEA/H/C/000961 OLANZAPINE MYLAN BS590, BS591 2008
EMEA/H/C/001085 OLANZAPINE GLENMARK 60679 2009
EMEA/H/C/001086 OLANZAPINE GLENMARK EUROPE 60679 2009
EMEA/H/C/001087 OLAZAX 60679 2009
EMEA/H/C/001088 OLAZAX DISPERZI 60679 2009
EMEA/H/C/001178 OLANZAPINE APOTEX OL 5063, OAN-P8-57.1 2010
a Current Licensing status: Not authorised.
Table 9 Generic Irbesartan medicinal products authorised in the EU.
Procedure number Product name Study Finalised regulatory evaluation (Year)
EMEA/H/C/001093 IRBESARTAN TEVA 1056 2009
EMEA/H/C/002510 SABERVEL GE03IRB/1/06 2012
EMEA/H/C/000962 IFIRMASTA IBA-P7-064 2008
Changing paradigms in bioequivalence trials 7The number of participants enroled in both studies, thirty
for each study, was similar to the mean number enroled for
the nine two-arm studies: twenty-four (n= 9, range: 21–28).
Duration of the studies was not speciﬁed in the EPARs.
4. Discussion
This study was carried out using information derived from
EPARs available on the EMA website (www.ema.europa.
eu). It is our opinion that the publication of EPARs not only
helps to foster and build trust in the EU regulatory network
and the manner in which risk-beneﬁt evaluation is carried
out by the EMA, but EPARs are information rich and help
provide the data required to be able to carry out regulatory
science research, albeit all the published information EPARs
could be improved by having the same level of details across
all products (European Medicines Agency, 2015b). The
results of this study (although based on a limited amount
of data as a low number of bioequivalence studies have been
identiﬁed for this review are still of value as publicly accessi-
ble information on these studies is scarce), suggest that dif-
ferent clinical strategies are being implemented by sponsors/
CROs to support a marketing authorisation that could result
in a decreased number of resources required to carry out the
scientiﬁcally robust BE studies that are required to the grant
a MA in line with the CHMP’s guideline on the investigation
of bioequivalence (CHMP, 2010a). Our review indicates that
generic manufacturers usually follow the same clinical devel-
opment programme and carry out a two period-crossover
design; however, there were exceptions, where changes could
have been introduced due to the impact of increased scientiﬁc
knowledge on the subject and due to changes in the regula-
tory framework (i.e. the EU guideline on BE was updated in
2010). Within the centralised marketing authorisation proce-
dure, some generic manufacturers have used other crossover
designs. For example, one generic manufacturer has used the
four period crossover design for capecitabine. Reasons forPlease cite this article in press as: Refalo, N. et al., Changing paradigms in bioequiv
perspective. Saudi Pharmaceutical Journal (2016), http://dx.doi.org/10.1016/j.jsps.20such a choice could relate to the possibility to estimate a
treatment effect even in the presence of a carry-over effect
as this design can provide estimates of the intra-subject vari-
ability and draw inference on the carry-over effect (Reed,
2012). In fact the usual choice of a four-period design is
when carryover effects are predicted. In Capecitabine’s case,
it is metabolised into active 50-DFCR, 50-DFUR, 5-FU and
FBAL. For all these compounds the half-lives are short,
reported at 0.85, 1.11, 0.66, 0.76 and 3.23 respectively
(CHMP, 2015). Therefore no carryover effect was expected
for studies with Capecitabine, yet this choice of study design
by one of the generic manufactures resulted in the need to
recruit few patients than the two-way crossover design and
was adequate to fulﬁl the criteria required to register the pro-
duct in the European Union. For telmisartan, although
absorption is rapid, the amount absorbed varies with food
resulting in a reduction in the area under the plasma
concentration-time curve (AUC0-1) of telmisartan of 6%
(40 mg dose) to approximately 19% (160 mg dose). However,
3 h after administration, plasma concentrations are similar if
telmisartan is administered with or without food. Telmisar-
tan is metabolised by conjugation to the glucuronide of the
parent compound. No pharmacological activity has been
shown for the conjugate (CHMP, 2013b). In this study, for
telmisartan/hydrochlorothiazide combination containing
products reviewed (similar to Capecitabine), no carry-over
effect was expected and the four-period studies required less
subjects than other designs. While for olanzapine- and
temozolomide-containing products, some dossiers contained
studies with 3-period studies and although this design did
not result in a decrease in the number of subjects recruited
into the trial or the centres required for the trial, were specif-
ically designed to support the registration of the generic med-
icine in non-EU territory (as the 3rd arm was carried with
non-EU product). It is clear that such a trial design provides
the advantage to reduce costs required to carryout another
BE study for ﬁling in a non-EU territory (like the US). Fromalence trials submitted to the EMA for evaluation – A clinical and regulatory
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8 N. Refalo et al.a pharmacokinetic point of view, no carryover effect is
expected (thus the study design was shown to be appropriate)
as Olanzapine is biotransformed in the liver by conjugative
and oxidative pathways. The major metabolite is 10-N-
glucuronide (but does not pass the blood brain barrier).
Cytochromes P450-CYP1A2 and P450-CYP2D6 contribute
to the formation of the N-desmethyl and 2-hydroxymethyl
metabolites which are both signiﬁcantly less active than the
parent compound olanzapine (CHMP, 2012f, 2009b). Clopi-
dogrel is extensively metabolised by the liver by two main
metabolic pathways: one mediated by esterases and leading
to hydrolysis into its inactive carboxylic acid derivative
(85% of circulating metabolites), and one mediated by mul-
tiple cytochromes P450. Clopidogrel is ﬁrst metabolised to a
2-oxo-clopidogrel intermediate metabolite. Subsequent meta-
bolism of the 2-oxo-clopidogrel intermediate metabolite
results in formation of the active metabolite, a thiol deriva-
tive of clopidogrel. The active metabolite is formed mostly
by CYP2C19 with contributions from several other CYP
enzymes, including CYP1A2, CYP2B6 and CYP3A4
(CHMP, 2011a). In the EU, it is expected that evaluation
of bioequivalence is based upon measured concentrations
of the parent compound since the Cmax of a parent com-
pound is usually more sensitive to detect differences between
formulations in absorption rate than Cmax of a metabolite.
Therefore, it is expected that problems with instability create
problems with detection and the use of a metabolite as a sur-
rogate for an active parent compound in the EU is not
encouraged, but can be justiﬁed by prospective applicants if
they show that the sensitivity of the analytical method for
measurement of the parent compound cannot be improved
and that it is not possible to reliably measure the parent
compound after single dose administration (CHMP, 2010a).
Applicants should also consider if their product is a highly
variable drug (HVD) whose intra-subject variability is larger
than 30%. If this is the case, then in the EU, the acceptance
criteria for Cmax can be widened to a maximum of 69.84–
143.19%; however, this must be thoroughly justiﬁed by
prospective applicants (CHMP, 2010a).
5. Conclusion
This study shows that in the generic industry, different study
designs are being carried out that lead to reductions in the
resources required for carrying out the study (such as the num-
ber of subjects recruited, the number of centres required and
the study duration). When fewer resources are required to reg-
ister a medicinal product, this could lead to an advantage to
generic manufacturers (such as to be ﬁrst on the market) by
making medicines more accessible to patients.
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